Bayer vs. Novartis eye-drug fight intensifies; Pfizer's thyroid med faces sales hurdles; AZ media chief jumps ship;

> Britain's cost-effectiveness gatekeepers backed a new use for Bayer's Eylea vision treatment, in patients with macular edema, stepping up its rivalry with Novartis' ($NVS) Lucentis drug. Report

> Pfizer ($PFE) will resume shipping its thyroid drug Levoxyl after a manufacturing snafu caused a long hiatus; the company now faces a challenge in regaining market share from AbbVie's ($ABBV) Synthroid and generic drugs. Report

> AstraZeneca's ($AZN) global head of media relations, Neil McCrae, has jumped ship to join Royal Mail as its deputy director of communications. Report

> KV Pharmaceutical ($KV.A) created a new maternal health division to focus on marketing products for pregnancy management and tapped Alere Health's Gregg Raybuck to be president of the unit. Report

> Forest Laboratories ($FRX) launched a new support program for chronic obstructive pulmonary disease patients using its treatments for the disease, Tudorza Pressair and Daliresp. Release

> India's Dr Reddy's Laboratories saw its stock surge today after it launched its injectable version of Imitrex, GlaxoSmithKline's ($GSK) migraine drug, in the U.S. Report

And Finally... Algeta shareholders have now tendered more than 97% of their shares to Bayer in the German drugmaker's 2 billion euro takeover. Report